9 Myths About Menopause and Libido That Are Leaving Women Undertreated
This one is personal for so many women who write to the site. The number who say their doctor shrugged and said 'that's just menopause' when they brought up low libido is genuinely upsetting. It is not just menopause. It is undertreated hormonal change — and there is a real difference.
Learn more about Rose →Myth: Low libido after menopause is just a normal part of aging
While libido does shift across a lifetime, the sharp decline many women experience around perimenopause and menopause is driven by specific hormonal changes — primarily the fall in estrogen, testosterone, and DHEA — not by age itself. Research distinguishes between age-related gradual change and the steeper, faster decline triggered by the hormonal transition, which is a treatable physiological event. Calling it 'just aging' conflates two different mechanisms and removes the incentive to investigate or treat.
Myth: Estrogen is the only hormone that matters for female sexual desire
Testosterone is the primary driver of sexual desire in women, just as it is in men — and ovarian testosterone production drops significantly in the years around menopause, often before estrogen does. Adrenal testosterone and DHEA also decline with age, meaning women lose libido-relevant androgens from multiple sources simultaneously. Focusing treatment conversations on estrogen alone misses the hormone most directly linked to the neurological experience of wanting sex.
Myth: If sex is painful, low desire is a psychological response — not a medical one
Genitourinary syndrome of menopause (GSM) causes vaginal dryness, thinning, and inflammation that makes penetrative sex genuinely painful, and the brain rapidly and logically associates sex with pain and begins suppressing desire as a protective response. This is not 'in the head' in any dismissive sense — it is a neurological avoidance loop with a clear physiological origin. Treating the underlying GSM with local estrogen or other options frequently reverses the desire loss without any psychological intervention required.
Myth: Antidepressants are an appropriate first-line treatment for low libido in menopause
SSRIs and SNRIs are among the most well-documented causes of reduced libido and delayed or absent orgasm in both sexes, yet some women in perimenopause are prescribed them for mood symptoms without discussion of how they may compound existing sexual side effects of hormonal change. Where low mood and low libido are both present, investigating the hormonal root cause first is a more logical sequence than adding a medication known to suppress sexual function. This is not an argument against antidepressants when genuinely needed — it is an argument for sequencing the investigation correctly.
Myth: Hypoactive sexual desire disorder (HSDD) is rare and only diagnosed in younger women
HSDD — persistent low sexual desire causing personal distress — is estimated to affect up to 40% of postmenopausal women, making it one of the most common and least-treated sexual health conditions in this population. It has formal diagnostic criteria, a recognised neurobiological basis involving dopamine and serotonin pathways, and approved pharmacological treatments, yet it remains dramatically underdiagnosed in midlife women. The combination of provider discomfort and patient embarrassment creates a gap between prevalence and treatment that is not seen at the same scale in other common conditions.
Myth: Testosterone therapy for women is experimental and unproven
A 2019 international consensus statement, representing the most comprehensive systematic review of the evidence to date, concluded that testosterone therapy is effective for postmenopausal women with HSDD and has a favourable safety profile at physiological doses. Multiple randomised controlled trials support improvements in desire, arousal, orgasm frequency, and sexual satisfaction. The fact that no testosterone product is formally licensed for women in most countries is a regulatory and commercial issue, not a reflection of the evidence base.
Myth: Low libido is always about relationship problems, not hormones
Relationship quality absolutely influences sexual desire — that is not in dispute — but the hormonal contribution operates independently of relationship satisfaction, meaning women in happy, healthy partnerships still experience clinically significant libido loss driven by falling testosterone and estrogen. Studies examining women before and after oophorectomy (surgical menopause) show immediate, dramatic drops in desire that cannot be explained by sudden relationship deterioration. Conflating the two means women in good relationships are frequently dismissed rather than investigated.
Myth: Once libido goes in menopause, it cannot be recovered
This is one of the most demoralising and least accurate myths circulating in popular culture. Randomised controlled trials of hormone therapy — including both estrogen-based HRT and testosterone — consistently show meaningful, measurable improvements in sexual desire, arousal, and satisfaction in postmenopausal women. Even women who have been postmenopausal for many years show responsiveness to hormonal intervention, though genitourinary tissue changes may take longer to reverse and may need local treatment alongside systemic therapy.
Myth: Bringing up low libido with a doctor is not worth the awkwardness
Surveys consistently show that the majority of women with sexual concerns in menopause do not raise them with their doctor — and that when they do, they often feel dismissed — yet the same surveys show that most women wish they had been asked. Healthcare providers who are trained in menopause medicine routinely ask about sexual function as part of a standard symptom review, because it is a recognised, treatable dimension of menopause experience. Finding a provider who treats this as a legitimate medical concern rather than an embarrassing aside is not always easy, but it is entirely reasonable to expect.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.